Highlights
– HARMONi‑6 (presidential symposium, ESMO) showed ivonescimab (PD‑1/VEGF bispecific) + paclitaxel/carboplatin improved IRRC‑assessed mPFS 11.1 vs 6.9 months vs tislelizumab+chemo (HR 0.60; P<0.0001).
– Objective response rate (ORR) 76% vs 54%; median duration of response (DoR) 11.2 vs 8.4 months. Benefit occurred irrespective of PD‑L1 status.
